Soft Tissue Sarcoma (STS)SAGESNCT07864870
Sarcoma Care Adherence and Survival in Strasbourg
An observational study of Soft Tissue Sarcoma (STS), run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Soft Tissue Sarcoma (STS)
- How many people
- 900 participants
- Where
- 1 siteFrance
- Study dates
- 27 Nov 2025to 27 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with suspected or confirmed soft tissue sarcoma presented at multidisciplinary tumor boards in Strasbourg between 2017 and 2024
Who may be able to join
- Patient aged 18 years or older at first multidisciplinary tumor board presentation
- Presented for multidisciplinary tumor board evaluation for soft tissue or visceral tumor
- First presentation between 01/01/2017 and 31/12/2024
- Absence of opposition to reuse of medical data for research purposes
Who cannot join
- Presence of opposition to reuse of medical data for research purposes
- Patient younger than 18 years at first presentation
- Bone tumors, gastrointestinal stromal tumors (GIST), or Kaposi sarcoma
- First presentation outside the study period
- Management outside Alsace-Moselle
- Duplicate records
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'hématologie-oncologie pédiatrique - CHU de Strasbourg - France
Strasbourg, 67091
Justine Gantzer, MD, 33 3 88 12 88 25, justine.gantzer@chru-strasbourg.fr
Justine Gantzer, MD
About this study
Official title: Sarcoma Adherence to Good Practice and Effect on Survival: A Retrospective Monocentric Study
This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024).
- Conditions
- Soft Tissue Sarcoma (STS)
- Keywords
- Sarcoma, Clinical Practice Guidelines, Overall Surviva
- Medical subject headings
- Sarcoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Adherence to Good Clinical Practice and Overall Survival
Evaluation of adherence to international guidelines using DELPHI criteria and assessment of overall survival defined as time from diagnosis to death from any cause
Measured: From diagnosis up to end of follow-up (2017-2024)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start27 Nov 2025
- Primary completion27 Jan 2027 (estimated)
- Study completion27 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Soft Tissue Sarcoma (STS)Studies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864870
- Sponsor's protocol ID
- 9950
- Acronym
- SAGES
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sarcoma Adherence to Good Practice and Effect on Survival: A Retrospective Monocentric Study
- ClinicalTrials.gov ID
- NCT07864870
- Acronym / sponsor ID
- SAGES / 9950
- Conditions
- Soft Tissue Sarcoma (STS)
- Keywords
- Sarcoma, Clinical Practice Guidelines, Overall Surviva
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 27 Nov 2025 (actual)
- Primary completion
- 27 Jan 2027 (estimated)
- Study completion
- 27 Mar 2027 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024).
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with suspected or confirmed soft tissue sarcoma presented at multidisciplinary tumor boards in Strasbourg between 2017 and 2024
Key inclusion criteria (4 listed)
- Patient aged 18 years or older at first multidisciplinary tumor board presentation
- Presented for multidisciplinary tumor board evaluation for soft tissue or visceral tumor
- First presentation between 01/01/2017 and 31/12/2024
- Absence of opposition to reuse of medical data for research purposes
Key exclusion criteria (6 listed)
- Presence of opposition to reuse of medical data for research purposes
- Patient younger than 18 years at first presentation
- Bone tumors, gastrointestinal stromal tumors (GIST), or Kaposi sarcoma
- First presentation outside the study period
- Management outside Alsace-Moselle
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Adherence to Good Clinical Practice and Overall Survival
Time frame: From diagnosis up to end of follow-up (2017-2024)
Evaluation of adherence to international guidelines using DELPHI criteria and assessment of overall survival defined as time from diagnosis to death from any cause
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
Related trials for Soft Tissue Sarcoma (STS)
Recruiting
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
Soft Tissue Sarcoma (STS)
RecruitingPhase 1
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
RecruitingPhase 2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
Sarcoma, Soft Tissue Sarcoma (STS)
Not yet recruitingPhase 2
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma (STS), Utidelone
Active, not recruitingPhase 2
Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk
Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Soft Tissue Sarcoma (STS), run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Justine Gantzer, MD (33 3 88 12 88 25, justine.gantzer@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adherence to Good Clinical Practice and Overall Survival (time frame: From diagnosis up to end of follow-up (2017-2024)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.